Mr. Berman continued, ''Victory on the legal battl

Mr. Berman continued, ''Victory on the legal battlefields with J&J is no longer enough for the company and its shareholders. It is time to substantially monetize those legal victories. J&J failed in their prior attempts to subvert our legitimate efforts to market our feature superior and inexpensive blood glucose test strip alternative. They will continue to fail through this pursuit of justice for their repeated violation of our patents with the infringement of the DECN subsidiaries owned US patents 6,153,069 and 6,413,411, over a period of time where J&J sold billions and billions of dollars in value for their test strips, where in the companies' opinion, every one of those test strips sold infringed on our patents.''

Mr. Berman concluded, ''The expected new DECN products being launched into the market, with DECN on the cusp of new IP insurance, and with J&J's Lifescan division sale pending, the DECN infringement case is expected to conclude sooner than we had anticipated, and we believe sooner than J&J anticipated.''

The first paragraph makes the case for a larger judgement amount, IMO. The second is a heads up to the time scale. I recall the IH board's discussion of a rumor that said something along the line of ...get the shares you want by the end of February. I am encouraged that we might see some conclusive discussion of this in the upcoming annual report (which has been bird-dogged at the bottom of the press release

DECN anticipates filing its 2017 Annual Report on or about March 31, 2018.).

Time will tell. For now I'll go back to holding my breath...*gulp*... :^\